Fungal cytochrome P450 enzymes (Fungal CYPs)

Fungal cytochrome P450 enzymes (CYPs) are a superfamily of heme-thiolate proteins that play critical roles in fungal physiology, including the biosynthesis of membrane sterols and the metabolism of endogenous and exogenous compounds (Park et al., 2011, PubMed). The most prominent therapeutic target within this group is lanosterol 14-alpha-demethylase, also known as CYP51, which is essential for producing ergosterol, the fungal equivalent of cholesterol (Lepesheva & Waterman, 2007, PubMed). Azole antifungals, such as fluconazole and voriconazole, exert their effect by binding to the heme iron within the CYP51 active site, thereby blocking the demethylation of lanosterol (Odds et al., 2003, Journal of Antimicrobial Chemotherapy). This inhibition leads to the depletion of ergosterol and the accumulation of toxic methylated sterol precursors, resulting in compromised membrane integrity and inhibited fungal growth (Whaley et al., 2017, Frontiers in Microbiology). Beyond ergosterol synthesis, fungal CYPs are involved in the degradation of environmental toxins and the synthesis of secondary metabolites like mycotoxins (Crešnar & Petrič, 2011, Biochimica et Biophysica Acta). However, the structural conservation between fungal and human CYPs can lead to significant drug-drug interactions and potential hepatotoxicity in patients (Zonios & Bennett, 2008, Drug Safety). Resistance to these agents is an increasing clinical concern, often mediated by mutations in the CYP51 gene or the upregulation of efflux pumps (Cools et al., 2013, PLoS Pathogens).

Other names

Fungal CYPsLanosterol 14-alpha-demethylaseCYP51Ergosterol biosynthesis enzymesHeme-thiolate monooxygenases

Inhibition of lanosterol 14-alpha-demethylase (CYP51) prevents the conversion of lanosterol to ergosterol, disrupting fungal cell membrane integrity.